Located in Plattsmouth, the facility expansion adds approximately 70,000 square feet to accommodate CreaBoost’s manufacturing, storage and distribution, the company said in a statement. Pilot production is expected to begin in March 2027, with full production targeted by Q2 2027, and the facility is designed for an annual capacity of 5 million kg.
“CreaBoost’s premium specification was previously manufactured by a single international partner and imported into the United States,” said Kevin Kerr, director of strategic initiatives, CreaBoost. “Domestic production will serve both global and U.S. markets, with an initial focus on domestic demand. In the near future, we will be announcing several significant strategic partnerships that have already embraced the opportunity to have domestically made creatine.”
Kerr noted that the brand has worked with its overseas partner to refine CreaBoost’s premium specification through improved sourcing and manufacturing, resulting in a highly pure creatine with improved dissolvability. The brand and its enhanced purity specification launched in May 2026.
“Format development, and innovative dosing and delivery options, have been ongoing — the improved dissolvability opened the door to great-tasting, stable new formats across the line,” Kerr said.
At SupplySide Global in October, the brand previewed the CreaBoost 2026 to 2027 lineup, which includes NutraSoft chewable tablets, soft chews, gummies and stick packs, and a creatine + protein bar, though the latter is still in development. NutraSoft chewable tablets are slated for November 2026, followed by soft chews in December and gummies and stick packs in Q1 2027. The creatine and protein bar is targeted for March 2027.
Investment and demand
The facility expansion represents an investment of more than $20 million, funded through a combination of internal reinvestment of operational cash flow along with bank financing, said Mark Faulkner, CEO and founder of Vireo Systems.
“This continues Vireo’s history of internally managing growth in a very disciplined manner so as to preserve a culture of research-based innovation and domestic manufacturing,” he said. “This approach has well-protected our long-term vision and has been a unique and important driving force of our business.”
Faulkner added that increasing consumer demand has been a factor, but not necessarily the primary factor for the facility expansion. Vireo Systems already manufactures CON-CRET Creatine HCl domestically, and creatine monohydrate is one of its largest inputs.
“This expansion builds on Vireo’s core focus on vertical integration and controlling our own supply chain as much as possible,” he said.
As for growth, the company explained this was just the beginning for CreaBoost as both a brand and an ingredient. Vireo Systems has development plans mapped out through 2030, positioning it to scale alongside the growing creatine market and the expanding body of research on its benefits, Kerr said.
“Creatine is being increasingly understood to be one of the most important supplements people can take for foundational health, and we are poised to help support the market demands associated with that knowledge.”
Kerr said Vireo has development plans mapped out through 2030, with research spanning areas including concussions, neurodegeneration, sarcopenia, menopause, longevity and more.
“To our knowledge, no company is doing more research on creatine and health-related topics,” he said.
